The series A financing is being co-led by founding investors Atlas Venture and Boulder Ventures, and includes additional investments from private individuals. The funding will be employed to expand Miragen’s initial R&D programs aimed at regulating microRNA for the treatment of heart failure and related diseases.
Bruce Booth, chairman of the board of directors at Miragen, said: “Heart failure remains a significant unmet medical need today, and Miragen’s innovative microRNA-based approach directly targets the key gene regulatory mechanisms underlying the disease. We look forward to contributing to the development of this exciting new class of drug candidates.”